March 25 (Bloomberg) — Dialysis centers run by DaVita HealthCare Partners Inc., Fresenius Medical Care AG and other companies aren’t being paid correctly by the Medicare program because the U.S. is miscalculating drug costs, government auditors said.

A report to be released today by the Health and Human Services Department’s Office of Inspector General recommended that the agency that runs Medicare recalculate its payments to dialysis centers “to reflect current trends in drug acquisition costs.” Prices paid by dialysis centers for Amgen Inc.’s Epogen, the most expensive drug they use, increased at least 17 percent from 2009 to 2012, according to the report. Prices for other drugs fell, often by more than Medicare estimated.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?


BenefitsPro Broker ExpoEvent

BenefitsPro Broker Expo will help attendees prepare for new issues, embrace new challenges and find new solutions.

Get More Information


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.